DeepMed Research

Ascendis Pharma Oncology Division A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma

Phase 2

Completed

Conditions: Head and Neck Neoplasms

Interventions: Drug: TransCon TLR7/8 Agonist
Drug: Pembrolizumab
Drug: TransCon IL-2 β/γ

First Posted Date: 2023-08-08

Last Posted Date: 2025-05-04

Lead Sponsor: Ascendis Pharma Oncology Division A/S

Target Recruit Count: 27

Registration Number: NCT05980598

Locations: 🇨🇳
Ascendis Investigational Site, Taoyuan, Taiwan
🇺🇸
Ascendis Pharma Investigational Site, Canton, Ohio, United States
🇪🇸
Ascendis Investigational Site II, Madrid, Spain

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Phase 1

Recruiting

Conditions: Advanced Solid Tumor
Locally Advanced Solid Tumor
Metastatic Solid Tumor
Platinum-resistant Ovarian Cancer
Post Anti-PD-1 Melanoma
2L+ Cervical Cancer
Neoadjuvant Melanoma
Neoadjuvant Non-Small Cell Lung Cancer
Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Post Anti-PD-(L)1 Small Cell Lung Cancer

Interventions: Drug: TransCon IL-2 β/γ
Drug: Trastuzumab emtansine (T-DM1)
Drug: TransCon TLR7/8 Agonist
Drug: Pembrolizumab
Drug: Trastuzumab
Drug: Chemotherapy drug
Procedure: Surgery

First Posted Date: 2021-10-18

Last Posted Date: 2025-05-02

Lead Sponsor: Ascendis Pharma Oncology Division A/S

Target Recruit Count: 345

Registration Number: NCT05081609

Locations: 🇨🇳
Ascendis Pharma Investigational Site, Taipei, Taiwan

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Locally Advanced Solid Tumor
Advanced Solid Tumor
Metastatic Solid Tumor
HPV-associated Cancers
Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)
Head and Neck Squamous Cell Carcinoma HNSCC
Neoadjuvant Melanoma

Interventions: Drug: TransCon TLR7/8 Agonist
Drug: Pembrolizumab

First Posted Date: 2021-03-16

Last Posted Date: 2024-10-30

Lead Sponsor: Ascendis Pharma Oncology Division A/S

Target Recruit Count: 188

Registration Number: NCT04799054

Locations: 🇦🇺
Ascendis Pharma Investigational Site, Frankston, Victoria, Australia
🇨🇳
Ascendis Investigational Site, Taipei City, Taiwan

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy